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Treatment persistenceTreatment persistence in first-line injectable disease-modifying therapies (DMT) for relapsing-remitting
multiple sclerosis (RRMS) is an important indicator of effectiveness. Identifying predictors of treatment
discontinuation is important as there are other therapies currently available and a growing range of
emerging drugs. We report a retrospective study of RRMS and clinically isolated syndrome patients fol-
lowed in a University Hospital during a 13-year period with the objective of identifying predictors of
treatment persistence. An evaluation of persistence on the first DMT, rates of DMT discontinuation,
and reasons and predictors of discontinuation was performed. A total of 410 patients were included,
69% female, with mean disease duration of 37.8 months, mean age of 34.2 years and mean follow-up time
of 6.1 years. The first DMT was glatiramer acetate (GA) in 27.56% of patients, interferon (IFN) b-1a intra-
muscular in 26.34%, IFNb-1b in 26.10%, IFNb-1a22 in 13.66% and IFNb-1a44 in 6.34%. Treatment was dis-
continued in 16.34% of patients after 1 year of treatment and in 50.24% of patients in the total follow-up
time, with a mean time for discontinuation of 39.80 months. Higher baseline Expanded Disability Status
Scale score was an independent predictor of treatment discontinuation (hazard ratio 1.35, p = 0.002).
After the first year, treatment persistence was 90.74% for IFNb-1a-IM, 88.46% for IFNb-1a44, 83.18% for
IFNb-1b, 83.19% for GA and 69.64% for IFNb-1a22 (p = 0.014). Lower frequency of administration was
associated with higher persistence rates. The most common reason for treatment discontinuation was
lack of efficacy in all DMT subgroups.
 2016 Elsevier Ltd. All rights reserved.1. Introduction 72% between the third and fifth year of treatment, with discontin-Treatment effectiveness encompasses the effect of treatment
under everyday conditions of care, resulting from a combination
of efficacy, safety, tolerability and patient satisfaction. Therefore,
treatment persistence is considered an important indicator of
effectiveness.
Injectable disease-modifying therapies (DMT) were, until
recently, the only first-line treatments approved for relapsing-
remitting multiple sclerosis (RRMS). In the pivot clinical trials of
this drugs, the rates of DMT persistence at the end of first year ran-
ged from 90% to 97% [1–4]. However, these results may not be ade-
quately extrapolated to the real world population, as lower rates of
treatment persistence have been reported in post-marketing
studies, with real-world studies describing rates of treatment per-
sistence from 78.5% to 90% after one year and dropping to 59% touation occurring mainly due to side effects and lack of efficacy
[5–8].
In this article, we present a retrospective study of RRMS and
clinically isolated syndrome (CIS) patients with the objective of
assessing treatment persistence for the first DMT and evaluating
the reasons and possible predictors of treatment discontinuation.
2. Materials and methods
This is a retrospective study including patients with RRMS,
according to McDonald Criteria of 2010, and CIS, followed in the
multiple sclerosis (MS) outpatient clinic of a university hospital.
The study included treatment naïve patients who were started
on first line DMT between 2000 and 2013. The following subgroups
of DMT were used: glatiramer acetate (GA), Interferon (IFN) b-1a
intramuscular (IM), IFNb-1a22, IFNb-1a44 or IFNb-1b.
Exclusion criteria included previous exposure to other treat-
ments, including immunosuppressive drugs (such as azathioprine,
mycophenolate mophetil, cyclophosphamide, mitoxantrone or
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74 I. Correia et al. / Journal of Clinical Neuroscience 33 (2016) 73–78methotrexate) and other DMT approved for RRMS (such as natal-
izumab, fingolimod or alemtuzumab), and previous inclusion in
clinical trials.
Clinical evaluation of the patients was performed in the outpa-
tient clinic with 6-month intervals and all the data collected was
recorded in our MS consultation database using the program
iMED.
Data collected comprised demographic data, including sex, age
at diagnosis and age at first treatment, clinical data, including dis-
ease duration, clinical presentation,relapses and disability score
assessed by the Expanded Disability Status Scale (EDSS) and treat-
ment data, including first DMT used and treatment adverse events.
First DMT treatment persistence, defined as months of continuous
use of the first DMT, and reasons for treatment discontinuation
were assessed.
Treatment discontinuation due to lack of efficacy was defined
by the treating physician in a standard manner, and considered
when there was disability progression, relapses or increase in
MRI lesion load. Treatment discontinuation due to adverse events
was considered when treatment was stopped or switched due to
important systemic or local reactions or infections. Pregnancy
was considered a reason for treatment discontinuation in patients
who stopped treatment because of pregnancy or while attempting
conception.
Accurate annualized relapse rate previous to the first DMT was
not available in many patients and therefore was not included in
the analysis.
Demographic characteristics are presented as means and stan-
dard deviations for continuous variables, and as frequencies and
percentages for categorical variables. Patient EDSS is described as
mean and standard deviation.
In our sample all the variables have a non-normal distribution,
except for age at MS diagnosis and age at DMT start, therefore non-
parametric tests were used. Wilcoxon Signed Ranks Test was used
to compare related samples, the Mann–Whitney Test to compare
different groups of patients and multivariable survival analyses
were used to identify predictors of treatment discontinuation.
Statistical significance was considered when p < 0.05, and 95% con-
fidence intervals (CI) were used in the graphs. IBM SPSS Statistics
(version 20.0) (IBM, Armonk, NY, USA) was used for the statistical
analysis.fi
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at3. Results
From a global population of 966 patients followed in our MS
outpatient clinic, 410 RRMS and CIS treatment-naïve patients were
started on a first line DMT between 2000 and 2013 and were
included in the study.Ta
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i3.1. Patient demographics
All the patients had Caucasian background, 68.54% (n = 281)
were female, the mean disease duration at treatment start was
37.8 months and the mean age at first treatment was 34.2 years.
The mean follow-up time was 6.1 ± 4.0 years.
Table 1 presents more details about the patient demographics
and also clinical presentation and EDSS at baseline.
The first treatment was glatiramer acetate (GA) in 113 patients
(27.56%), Interferon b (IFNb)-1a intramuscular (IFNb-1aIM) in 108
patients (26.34%), IFNb-1b in 107 patients (26.10%), IFNb-1a22 in
56 patients (13.66%) and IFNb-1a44 in 26 patients (6.34%).
Comparing the DMT subgroups, it was noted a tendency to
lower age at disease onset of GA patients (31.17 ± 10.54 years,
p = 0.051) and a higher baseline EDSS in the IFNb-1b (2.56 ± 1.12)
and IFNb-1a22 (2.33 ± 0.98) subgroups (p < 0.001) (Table 1).
Table 2
Clinical characteristics of patients with RRMS commencing first-line treatment with DMT according to persistence on the first DMT
Persistence Discontinuation p value
Female, n (%) 138 (67.65) 143 (69.42) 0.70
Age at RRMS diagnosis, years (SD) 35.71 (±10.95) 32.92 (±16.41) 0.001#
Age at first treatment, years (SD) 36.78 (±10.62) 32.79 (±9.94) 0.020#
Disease duration since diagnosis at
treatment start, months (SD)
4.52 (±14.93) 3.94 (±13.11) 0.993
EDSS at baseline, (SD) 2.06 (±0.99) 2.22 (±0.92) 0.017#
Presentation*, n (%) 0.959
Supratentorial 27 (18.37) 32 (18.82)
Optic pathways 32 (21.77) 37 (21.76)
Infratentorial 37 (25.17) 39 (22.94)
Spinal 34 (23.13) 43 (25.29)
Multiple systems 17 (11.56) 19 (11.18)
# p value <0.05 was considered statistically significant.
* Incomplete data.
DMT = disease-modifying therapy, EDSS = Expanded Disability Status Scale, n = number, RRMS = relapsing-remitting multiple sclerosis, SD = standard deviation.
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subgroups regarding sex, clinical presentation, mean disease dura-
tion or age at treatment beginning.3.2. Treatment persistence
After one year of treatment, 16.34% of patients (n = 67) discon-
tinued treatment, and after the total follow-up time
(6.07 ± 3.98 years) treatment was discontinued in 50.24%, with a
mean period for discontinuation of 39.80 ± 35.73 months.3.2.1. Treatment persistence based on clinical characteristics
Clinical characteristics of the different groups of patients
according to the persistence in the first DMT are presented in
Table 2.
Patients who persisted on the first DMT were significantly older
at treatment start than those who discontinued treatment (36.78
vs. 32.79, p = 0.02), however, after multivariate analysis, age was
not an independent predictor of treatment persistence.Fig. 1. Treatment persistence by baseline Expanded Disability Status Scale (EDSS).Higher EDSS at baseline was an independent predictor of treat-
ment discontinuation in multivariate analysis (hazard ratio [HR]
1.35, p = 0.002). EDSS stratification using a cut-off value of 2.0,
revealed a higher risk of treatment discontinuation for patients
with a baseline EDSS higher than 2.0 (HR 1.52, p = 0.012), as shown
in Figure 1.
Sex and disease duration were not factors of treatment persis-
tence in our population.
3.2.2. Treatment persistence based on the first DMT
The treatment persistence among the different DMT groups is
presented in Figure 2 and Table 3.
After one year of treatment, the persistence rate was signifi-
cantly lower for IFNb-1a22 (69.64%) compared to the other DMT
subgroups (Breslow Test p = 0.023) (Fig. 3). However, when consid-
ering the entire follow-up period, no significant differences were
found between the DMT subgroups. After adjustment for baseline
EDSS, treatment persistence on IFN-b1a22 was significantly lower
than on IFN-b1aIM (HR = 0.48, CI 0.38–0.81, p = 0.006), without
significant differences regarding the other DMT subgroups.
3.3. Discontinuation
A total of 206 patients discontinued treatment. The most com-
mon reason for treatment discontinuation was lack of efficacyFig. 2. Treatment persistence by disease-modifying therapies (DMT) subgroups
IFN = interferon, IM = intramuscular.
Fig. 3. Treatment persistence by disease-modifying therapy (DMT) subgroup
adjusted for baseline Expanded Disability Status Scale (EDSS) IFN = interferon,
IM = intramuscular.
76 I. Correia et al. / Journal of Clinical Neuroscience 33 (2016) 73–78(69.42%), followed by adverse events (27.18%) and pregnancy
(3.40%). No significant differences in the reasons for discontinua-
tion were found between the DMT subgroups, as shown in Figure 4.
In most cases of lack of efficacy (89.51%) discontinuation was
due to clinical factors, relapses or disability progression, with theTable 3
Treatment persistence in patients with relapsing-remitting multiple sclerosis commencing
All DMT
(n = 410)
GA (n = 113) IFN
(n
Follow-up time, years (SD) 6.07 (±3.98) 5.56 (±4.11) 5.9
Treatment persistence after one-year, n (%) 343 (83.66) 94 (83.19) 98
DMT persistence, months (SD) 53.02 (±42.93) 50.80
(±37.73)
56
Treatment persistence at the end of follow-up,
n (%)
204 (49.76) 52 (46.02) 65
# p value <0.05 was considered statistically significant.
DMT = disease-modifying therapy, GA = glatiramer acetate, IFN = interferon, IM = intram
Fig. 4. Reasons for treatment discontinuation in patients with relapsing-remitting multip
by DMT subgroup. IFN = interferon, IM = intramuscular.remaining cases being due to significant MRI lesion load increase
(10.49%).
The most common adverse event reported was systemic reac-
tions such as flu-like syndrome, although local reactions such as
exuberant inflammatory signs at injection site or lipoatrophy
related to repeated injections were also frequent.
The treatments performed after stopping the initial DMT are
presented in Table 4.4. Discussion
This study evaluated the persistence in the first DMT in a large
cohort of RRMS and CIS patients during a mean follow-up period of
six years, and is one of the studies evaluating real-world treatment
persistence with longer duration.
Although several possible predictors of treatment persistence
were assessed, including sex, age at onset of RRMS, clinical presen-
tation, disease duration, EDSS at baseline and the subgroup of DMT
used, statistical significance was found only for baseline EDSS.
As previously observed in several studies, baseline EDSS
showed to have a significant impact in treatment persistence, with
a high EDSS score being a predictor of treatment discontinuation
[6,8–11]. In fact, differences are evident even with a low cut-off
score, with patients with baseline EDSS above 2 having 1.7-fold
increased risk of discontinuing first treatment. This finding was
independent of sex, age and disease duration, and is probably
explained by the fact that treatment is more promptly switched
in MS patients with higher clinical disability in order to prevent
further disease progression.first-line treatment with DMT by DMT subgroup
b-1aIM
= 108)
IFNb-1b
(n = 107)
IFNb-1a22
(n = 56)
IFNb-1a44
(n = 26)
p
value
8 (±3.48) 6.34 (±4.11) 6.80 (±4.12) 6.04 (±4.48) 0.367
(90.74) 89 (83.18) 39 (69.64) 23 (88.46) 0.014#
.57 (±43.06) 50.17 (±44.04) 51.54 (±48.60) 62.85 (±46.92) 0.322
(60.19) 53 (49.53) 22 (39.29) 12 (46.15) 0.094
uscular, n = number, SD = standard deviation.
le sclerosis commencing first-line treatment with disease modifying therapy (DMT)
Table 4
Subsequent therapy after stopping the initial DMT in patients with RRMS commenc-
ing first-line treatment with DMT
Initial DMT Subsequent DMT n (%)
IFNb-1a22 IFNb-1a44 12 (35.29)
GA 8 (24.53)
Immunosuppression 4 (11.76)
IFNb-1b 3 (8.82)
IFNb-1aIM 3 (8.82)
Natalizumab 2 (5.88)
Fingolimod 1 (2.94)
Glatiramer Acetate IFNb-1b 19 (31.15)
Immunosuppression 11 (18.03)
IFNb-1aIM 9 (14.75)
Natalizumab 9 (14.75)
Fingolimod 6 (9.84)
IFNb-1a22 4 (6.56)
IFNb-1a44 1 (1.64)
None 2 (3.28)
IFNb-1a44 Natalizumab 4 (28.57)
GA 3 (21.43)
IFNb-1a22 3 (21.43)
IFNb-1aIM 2 (12.29)
None 2 (12.29)
IFNb-1b Natalizumab 16 (29.63)
Immunosuppression 14 (27.78)
GA 9 (16.67)
Fingolimod 7 (12.96)
IFNb-1aIM 3 (5.56)
IFNb-1a44 2 (3.70)
None 3 (5.56)
IFNb-1aIM IFNb-1b 11 (25.58)
GA 8 (18.60)
Natalizumab 7 (16.28)
Immunosuppression 7 (16.28)
Fingolimod 5 (11.63)
IFNb-1a22 3 (6.98)
IFNb-1a44 2 (4.65)
Note: Immunosuppression includes cyclophosphamide, mitoxantrone, azathioprine
and mycophenolate mofetil.
DMT = disease-modifying therapy, GA = glatiramer acetate, IFN = interferon,
IM = intramuscular, n = number.
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sis, a trend to higher rates of treatment discontinuation was found
in younger patients, which is in accordance with previous reports
[10]. A more active relapsing disease in early stages of the disease
with indication to switch to more effective treatments may explain
this finding.
The DMT used was also a predictor of treatment discontinuation
in our population, even after adjusting for baseline EDSS, with a
higher discontinuation rate found for IFNb-1a22, which was also
switched earlier than the other DMTs. This finding may be a bias,
as in our Clinic there is a low threshold to switch patients from
IFNb-1a22 to the higher dosage formulation available, IFNb-1a44,
as occurred in 36.4% of these patients. This has not been reported
in previous studies, as the two formulations of subcutaneous
IFNb-1a are usually not discriminated [9,10]. Higher persistence
rates were observed with IFNb-1aIM, which may be related with
a higher patient adherence to a treatment with a lower frequency
of administration, as reported in a large study addressing treat-
ment adherence to injectable therapies [12].
Unlike several previous reports, we found no association
between female sex and treatment discontinuation [6,8,9,13].
Overall, 16.3% of patients discontinued treatment during the
first year of treatment, and 50.2% discontinued treatment during
the total follow-up period, with a mean time for discontinuation
of treatment of 39.8 months. In most cases, treatment was
switched due to lack of efficacy of the DMT being used.The discontinuation rate due to adverse events is variable
among the available studies, with rates reported ranging from
14.7% to 58% [5–7,10,14]. In our population the discontinuation
rate due to adverse events was relatively low (27.18%). This may
be explained by the fact that, in our clinic, before treatment begin-
ning, qualified nurses explain to the patients the best way of
managing the injection devices and providing the injection and
also correct misuse of the device during treatment in cases of local
side effects related to the injections. Additionally, symptomatic
treatments, such as nonsteroidal anti-inflammatory drugs and
paracetamol, are routinely used by physicians in order to minimize
systemic side effects.
This study presents some limitations, including the different
sample size for each DMT subgroup and being a retrospective
study, with incomplete data regarding causes of treatment discon-
tinuation and baseline annualized relapse rate in a significant
number of patients.5. Conclusions
Treatment persistence is an important indicator of effectiveness
and the identification of predictors to discontinuation is important
in clinical practice, as other therapies are currently available. In our
population, approximately 15% of patients discontinued first DMT
after 1 year and 50% in the total follow-up time. Higher baseline
EDSS was the only independent predictor of treatment discontinu-
ation as the threshold for treatment switch is lower in patients
with more disability. The DMT used was also a predictor of treat-
ment persistence with higher persistence rates for DMT with lower
frequency of administration. The most common reason for treat-
ment discontinuation was lack of efficacy, clinically or radiologi-
cally determined, in all DMT subgroups.Conflicts of Interest/Disclosures
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